Key result
Antiretroviral therapy and chronic HIV infection are linked to unexpected cardiovascular events in young patients.
Answers are grounded in this paper and cite their sources.
Soon after the introduction of protease inhibitors and nonnucleoside reverse-transcriptase inhibitors for the management of human immunodeficiency virus (HIV) infection, clinicians observed unexpected cardiovascular events among patients receiving these new, combination, “highly active” antiretroviral regimens. Angina, myocardial infarction, and stroke were seen in patients who were relatively young. Providers became suspicious that these events were related either to chronic HIV infection, since patients were surviving for longer periods than they had in the past, or to the new anti-HIV regimens, which are associated with substantial metabolic abnormalities.Between 1998 and 2003, several reports appeared to validate clinicians' concerns. The French . . .
No takes yet. Share an insight, caveat, or question.
Sklar et al. (2003) conducted an editorial in Human immunodeficiency virus (HIV) infection and cardiovascular disease. Combination antiretroviral therapy (protease inhibitors and nonnucleoside reverse-transcriptase inhibitors) was evaluated on Cardiovascular events (angina, myocardial infarction, and stroke). Combination antiretroviral regimens and chronic HIV infection were suspected to be linked to unexpected cardiovascular events in relatively young patients in reports published between 1998 and 2003.
Synapse has enriched 10 related papers. Consider them for comparative context: